In April 2017, the new drug midostaurin (Rydapt; Novartis Pharmaceuticals, Inc) received approval by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed FLT3-mutated AML (Levis, 2017). The gene discussed is FLT3; the disease is acute myeloid leukemia.